Marzo 2023 - Nouscom

Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy

BASEL, Switzerland – 15th March 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new [...]

NOUSCOM ANNOUNCES THE PROMOTIONS OF LOREDANA SIANI TO VICE PRESIDENT OF TECHNICAL AND CMC DEVELOPMENT, TIFFANY BROOKE MULLER TO SENIOR VICE PRESIDENT OF FINANCE AND MORENA D’ALISE TO VICE PRESIDENT OF IMMUNOLOGY

We are glad to announce the following promotions of our team members: Loredana Siani to Vice President of Technical and CMC Development, Tiffany Brooke Muller to Senior Vice President of Finance [...]

Nouscom announces appointment of Sarah Runswick as Senior Director of Clinical Science

We are thrilled to welcome Sarah Runswick as Senior Director of Clinical Science at Nouscom. Sarah is an experienced global clinical scientist with over 20 years expertise in early and late stage [...]